Azaya Therapeutics, Inc.
๐บ๐ธUnited States
- Country
- ๐บ๐ธUnited States
- Ownership
- Subsidiary
- Established
- 2002-01-01
- Employees
- 11
- Market Cap
- -
Clinical Trials
2
Active:0
Completed:1
Trial Phases
1 Phases
Phase 1:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)โข Click on a phase to view related trials
Phase 1
2 (100.0%)A Crossover Bioequivalence Study of Intravenously Administered ATI0918 and DOXIL/CAELYX in Patients With Ovarian Cancer
Phase 1
- Conditions
- Ovarian CancerCancerOvarian TumorMalignant Female Reproductive System NeoplasmOvarian Epithelial Cancer Recurrent
- Interventions
- Drug: DOXIL/CAELYXDrug: ATI-0918
- First Posted Date
- 2012-10-26
- Last Posted Date
- 2015-01-15
- Lead Sponsor
- Azaya Therapeutics, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT01715168
- Locations
- ๐บ๐ธ
Yakima Valley Memorial Hospital - North Star Lodge, Yakima, Washington, United States
๐จ๐ฆCentre Hospitalier de L'Universite de Montreal (CHUM), Montreal, Quebec, Canada
Safety Study of a Liposomal Docetaxel Formulation in Patients With Solid Tumors Who Have Failed Previous Therapies
Phase 1
Completed
- Conditions
- Ovarian CancerSolid TumorBreast CancerPancreatic CancerNon-Small Cell Lung
- Interventions
- Drug: ATI-1123 (active drug = docetaxel)
- First Posted Date
- 2009-12-31
- Last Posted Date
- 2012-09-06
- Lead Sponsor
- Azaya Therapeutics, Inc.
- Target Recruit Count
- 29
- Registration Number
- NCT01041235
- Locations
- ๐บ๐ธ
Mary Crowley Cancer Research Centers (MCCRC), Dallas, Texas, United States
๐บ๐ธCancer Therapy and Research Center (CTRC), San Antonio, Texas, United States
News
No news found